The Kinase Inhibitor Imatinib - An Immunosuppressive Drug?

By  

Current Cancer Drug Targets, Vol. 7, Iss. 3, 2007-05 ,pp. : 251-258

Bentham Science Publishers

Access to resources Recommend Favorite

Drug resistance and BCR-ABL kinase domain mutations in Philadelphia chromosome–positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in the frequency of mutation involvement

By Soverini Simona   De Benedittis Caterina   Papayannidis Cristina   Paolini Stefania   Venturi Claudia   Iacobucci Ilaria   Luppi Mario   Bresciani Paola   Salvucci Marzia   Russo Domenico   Sica Simona   Orlandi Ester   Intermesoli Tamara   Gozzini Antonella   Bonifacio Massimiliano   Rigolin Gian Matteo   Pane Fabrizio   Baccarani Michele   Cavo Michele   Martinelli Giovanni  

Cancer, Vol. 120, Iss. 7, 2014-04 ,pp. : 1002-1009

Blackwell Publishing

Access to resources Recommend Favorite

Pazopanib, a potent orally administered small-molecule multitargeted tyrosine kinase inhibitor for renal cell carcinoma

By Sonpavde Guru   Hutson Thomas E   Sternberg Cora N  

Expert Opinion on Investigational Drugs, Vol. 17, Iss. 2, 2008-02 ,pp. : 253-261

Informa Healthcare

Access to resources Recommend Favorite

Oncogenic Variant RON160 Expression in Breast Cancer and its Potential as a Therapeutic Target by Small Molecule Tyrosine Kinase Inhibitor

By  

Current Cancer Drug Targets, Vol. 13, Iss. 6, 2013-07 ,pp. : 686-697

Bentham Science Publishers

Access to resources Recommend Favorite

Imatinib mesylate promising for CML

By  

Inpharma, Vol. 1, Iss. 1303, 2001-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite